id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
301,,,,,,,,,,,,,,,2024-06-13T13:00:04+06:00,BSH - H11911064454,Right,Tamoxifen,2020-07-25,,"Neoadjuvant Chemo AC x 4 > 12 weeks of adjuvant chemo with Paclitaxel-Trustuzumab on
23.10.19 > Maintenance Trastuzumab, C13 completed on 25/07/20",2023-05-09,,2023-11-16,,2020-09-23,,2020-06-30,Breast,292,Upper middle class,BSBSC-240000292,MRS. SHAMIMA YEASMIN,1711362287,1973-12-15,Female,,,,,Prof Dr Qamruzzaman Chowdhury,BSH,2.0,Continuous Maintenance,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,C50.4- Upper-outer quadrant of breast,Breast,Right,,,Stable,Alive,CR,,,,,,,,,,,CR,,,,,,,,,,
